Physician profile
Maria Charron
NPI 1073574091
$1,431.73
in general payments reported to CMS, 2019-2025
25 companies · $60.47 in 2025
The $60.47 reported for 2025 was less than what a typical General Practice provider received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $370 · 2020: $124 · 2021: $154 · 2022: $218 · 2023: $350 · 2024: $156 · 2025: $60.47.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $566.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $566.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $282.23 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $194.77 | 2019-2022 | |
| Lilly USA, LLC | $108.56 | 2022-2024 | Mounjaro, Trulicity, Zepbound |
| Esperion Therapeutics, INC. | $94.35 | 2020-2024 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $81.34 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.62 | 2021-2024 | Jardiance |
| Abbvie INC. | $72.32 | 2021 | |
| Abbott Laboratories | $60.89 | 2020-2023 | Freestyle Libre 3 |
| Pfizer INC. | $56.59 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $53.22 | 2019 | |
| Astellas Pharma US INC | $41.97 | 2019-2020 | |
| Radius Health, INC. | $37.51 | 2023-2024 | Tymlos |
| Almatica Pharma LLC | $37.25 | 2025 | Teriparatide, Loreev Xr |
| Glaxosmithkline, LLC. | $36.69 | 2020-2025 | Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.69 | 2023-2024 | Trulance, Xifaxan |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Springworks Therapeutics, INC. | $20.60 | 2024 | Ogsiveo |
| Paratek Pharmaceuticals, INC. | $20.05 | 2023 | Nuzyra |
| Nevro Corp. | $19.23 | 2023 | Senza |
| Kowa Pharmaceuticals America, INC. | $16.84 | 2021 | |
| Exact Sciences Corporation | $16.10 | 2023 | Cologuard Collection Kit |
| Tolmar, INC. | $16.10 | 2023 | |
| Azurity Pharmaceuticals, INC. | $15.61 | 2023 | Edarbi |
| Astrazeneca Pharmaceuticals LP | $15.42 | 2023 | Farxiga |
| Allergan, INC. | $13.39 | 2020 | |
| Merck Sharp & Dohme LLC | $13.39 | 2024 | Capvaxive, Gardasil, Gardasil 9 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Charron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.